ArticleDiagnostics (Basel, Switzerland)2024
Performance of Elecsys
Article in Diagnostics (Basel, Switzerland), 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
6 citing papers in PubMed.
- Comprehensive Evaluation of the Elecsys HCV Duo Immunoassay for Active Hepatitis C Detection: Insights From the DEPCDUO Study.Journal of medical virology · 2026Article
- Monoclonal antibody development against the Hepatitis C virus core protein enables rapid antigen detection.Scientific reports · 2026Article
- The usefulness of a simultaneous immunoassay for hepatitis C virus antigen-antibody using the ELECSYS HCV Duo assay.Hepatology forum · 2026Article
- The application of Electrochemiluminescence Immunoassay (ECLIA) in the detection of HIV infectious markers in blood screening.Pakistan journal of medical sciences · 2025Article
- Article
- Hepatitis C Virus-Core Antigen: Implications in Diagnostic, Treatment Monitoring and Clinical Outcomes.Viruses · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
BACKGROUND/
objectivesThe Elecsys
methodsBlood samples from 100 healthy controls, as well as 64 HCV mono-infection and 136 HCV-HIV coinfections, were collected before and 12-24 weeks after DAAs. The assay performance for determining active infection at baseline and SVR was compared with HCV RNA.
resultsOverall, 156 (78.0%) of HCV-infected patients had HCV genotype 1, and the SVR rate was 96.5%. The sensitivity, specificity, and area under the ROC curve (AUROC) for HCV diagnosis at baseline were 99.50% (95% confidence interval [CI], 96.82-99.97%), 100% (95%CI, 95.39-100%), and 0.998 (95%CI, 0.992-1.003), respectively. The corresponding results for HCV-Ag in determining SVR were 57.14% (95%CI, 20.24-88.19%), 97.41% (95%CI, 93.73-99.04%), and 0.773 (95%CI, 0.543-1.003), respectively. The assay also exhibited comparable sensitivity and specificity between HCV mono- and coinfection.
conclusionsOur study showed that the Elecsys
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.